^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
utidelone IV (UTD1)
i
Other names: UTD1, UTD-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Beijing Biostar Technologies, Luye Group
Drug class:
Microtubule inhibitor, Tubulin polymerization promoter
Related drugs:
2d
A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors (clinicaltrials.gov)
P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
New P2 trial
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • RET fusion • ALK fusion • ALK mutation • RET mutation • ROS1 fusion • EGFR positive • NTRK fusion
|
Avastin (bevacizumab) • etoposide IV • utidelone IV (UTD1)
1m
A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy (ChiCTR2500112307)
P=N/A, N=48, Recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
New trial
|
utidelone IV (UTD1)
1m
Study on the efficacy of Utidelone combined with Anotinib in the treatment of advanced Non-Small Cell Lung Cancer (ChiCTR2500115269)
P2, N=61, Not yet recruiting, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Un
New P2 trial
|
ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK positive • ALK fusion
|
Focus V (anlotinib) • utidelone IV (UTD1)
1m
Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. (PubMed, BMC Med)
The combination of inetetamab, camrelizumab, and utidelone demonstrated promising efficacy and a manageable safety profile in heavily pretreated patients with HER2-positive MBC. These findings support this regimen as a viable treatment option in this setting and warrant further investigation in randomized controlled trials.
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • Cipterbin (inetetamab) • utidelone IV (UTD1)
1m
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer (clinicaltrials.gov)
P2, N=32, Not yet recruiting, Zhongnan Hospital
New P2 trial
|
Loqtorzi (toripalimab-tpzi) • utidelone IV (UTD1)
3ms
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
Enrollment status
|
gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
6ms
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases (clinicaltrials.gov)
P2, N=120, Recruiting, Biostar Pharma, Inc. | Initiation date: Jan 2025 --> Jul 2025
Trial initiation date
|
capecitabine • utidelone IV (UTD1)
6ms
EXPRESS: Utidelone induces mechanical and cold allodynia in mice via TRPA1 activation. (PubMed, Mol Pain)
Utidelone (UTD1), an epothilone analogue recently approved in China for treating metastatic breast cancer, is recommended in conjunction with capecitabine for patients who have not responded to first-line therapies. Administration of the TRPA1 antagonist HC-030031 significantly alleviated mechanical and cold allodynia in the UTD1-induced pain model, as did two antioxidants, Mito-tempo and edaravone. This study proposes new approaches for mitigating pain caused by UTD1.
Preclinical • Journal
|
ATF4 (Activating Transcription Factor 4) • SOD2 (Superoxide Dismutase 2) • TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1)
|
capecitabine • utidelone IV (UTD1)
7ms
Utidelone induces apoptosis and autophagy in small cell lung cancer cells through the ROS/AMPK signaling pathway (PubMed, Zhonghua Zhong Liu Za Zhi)
Furthermore, the proportions of apoptosis-positive cells and p-AMPKα-positive cells in the UTD1 group were significantly higher compared to the control group, while the levels of Ki-67 positivity were significantly reduced. UTD1 inhibits SCLC cell proliferation, induces G2/M phase arrest, and promotes cell apoptosis and autophagy through the activation of the ROS/AMPK signaling pathway.
Journal
|
CCNA2 (Cyclin A2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • CCNB1 (Cyclin B1)
|
utidelone IV (UTD1)
7ms
A Clinical Study of Utidelone Combined with Tegafur-Gimeracil-Oteracil Potassium (S-1), Anlotinib, and Sintilimab as First-Line Therapy for HER2-Negative Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma (ChiCTR2500104634)
P2, N=35, Not yet recruiting, Shanghai Changzheng Hospital; Shanghai Changzheng Hospital
New P2 trial
|
Focus V (anlotinib) • Tyvyt (sintilimab) • Teysuno (gimeracil/oteracil/tegafur) • utidelone IV (UTD1)
7ms
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
P3, N=192, Enrolling by invitation, Sun Yat-sen University
New P3 trial
|
gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)
8ms
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. (PubMed, JAMA Oncol)
This treatment approach warrants further validation in a randomized clinical trial. ClinicalTrials.gov Identifier: NCT05357417.
Clinical • P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Avastin (bevacizumab) • Airuituo (bevacizumab biosimilar) • utidelone IV (UTD1)
Share via
